Valuation Core Laboratories Inc. Deutsche Boerse AG
Stocks
HJ1
US21867A1051
Business Support Services
|
Market Closed -
Deutsche Boerse AG
15:43:33 2026-08-17 EDT
|
5-day change | 1st Jan Change | ||
| 10.70 EUR | 0.00% |
|
+3.88% | -21.32% |
| 07-30 | Core Laboratories Inc., Q2 2026 Earnings Call, Jul 30, 2026 | |
| 07-29 | Core Laboratories Inc. Provides Earnings Guidance for the Third Quarter of 2026 | CI |
Company Valuation: Core Laboratories Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,033 | 939.9 | 825.1 | 812.7 | 746.4 | 579.1 | - |
| Change | - | -8.98% | -12.21% | -1.51% | -8.16% | -22.42% | - |
| Enterprise Value (EV) | 1,204 | 1,097 | 973.2 | 919.7 | 746.4 | 579.1 | 579.1 |
| Change | - | -8.87% | -11.28% | -5.5% | -18.84% | -22.42% | 0% |
| P/E | 53.1x | 48.3x | 20.5x | 26.2x | 23.6x | 30.4x | 16.7x |
| PBR | 6.47x | 5.02x | - | - | - | - | - |
| PEG | - | - | 0x | -1.1x | 7.79x | -0.8x | 0.2x |
| Capitalization / Revenue | 2.2x | 1.92x | 1.62x | 1.55x | 1.42x | 1.14x | 1.08x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.14x | 1.08x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 10.7x | 8.44x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 14.4x | 10.3x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 25.9x | 11.9x |
| FCF Yield | 2.23% | 1.57% | 1.72% | 5.34% | 3.48% | 3.87% | 8.39% |
| Dividend per Share 2 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Rate of return | 0.18% | 0.2% | 0.23% | 0.23% | 0.25% | 0.32% | 0.32% |
| EPS 2 | 0.42 | 0.42 | 0.86 | 0.66 | 0.68 | 0.415 | 0.755 |
| Distribution rate | 9.52% | 9.52% | 4.65% | 6.06% | 5.88% | 9.64% | 5.3% |
| Net sales 1 | 470.3 | 489.7 | 509.8 | 523.8 | 526.5 | 510.1 | 534.9 |
| EBITDA 1 | 70.81 | 61.98 | 76.96 | 80.2 | 73.34 | 54 | 68.64 |
| EBIT 1 | 52.29 | 44.82 | 61.18 | 65.25 | 58.7 | 40.09 | 56.34 |
| Net income 1 | 19.73 | 19.45 | 40.94 | 31.4 | 31.8 | 19.21 | 35.16 |
| Net Debt | 170.9 | 157 | 148 | 107 | - | - | - |
| Reference price 2 | 22.31 | 20.27 | 17.66 | 17.31 | 16.03 | 12.62 | 12.62 |
| Nbr of stocks (in thousands) | 46,290 | 46,371 | 46,724 | 46,950 | 46,563 | 45,885 | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 1/29/25 | 2/4/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 25.44x | 2.85x | 12.83x | 3.38% | 22.81B | |
| 27.86x | 4.84x | 17.76x | 0.75% | 15.57B | |
| 20.07x | 2.87x | 11.82x | 1.32% | 3.8B | |
| -35.4x | 1.53x | 9.88x | -.--% | 2.11B | |
| 12.25x | - | - | 2.67% | 2.1B | |
| 22.08x | - | - | 2.31% | 1.64B | |
| Average | 12.05x | 3.02x | 13.07x | 1.74% | 8B | |
| Weighted average by Cap. | 22.44x | 3.49x | 14.34x | 2.14% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLB Stock
- HJ1 Stock
- Valuation Core Laboratories Inc.
Select your edition
All financial news and data tailored to specific country editions
